STOCK TITAN

Oncolytics Biotech Inc - ONCY STOCK NEWS

Welcome to our dedicated page for Oncolytics Biotech news (Ticker: ONCY), a resource for investors and traders seeking the latest updates and insights on Oncolytics Biotech stock.

Oncolytics Biotech Inc (ONCY) is a clinical-stage biotech company advancing pelareorep, an innovative oncolytic virus immunotherapy targeting multiple cancer types. This dedicated news hub provides investors and researchers with centralized access to corporate developments and scientific progress updates.

Track critical updates including clinical trial results, regulatory milestones, and strategic partnerships. Our curated collection features press releases spanning Phase 2 breast cancer studies, pancreatic cancer research advancements, and manufacturing capacity expansions. Regular updates ensure timely awareness of key developments in HR+/HER2- metastatic breast cancer trials and other high-priority programs.

Discover verified information on pelareorep's mechanism of action, trial design specifics, and intellectual property developments. The resource eliminates the need by aggregating essential updates from randomized controlled studies to manufacturing quality initiatives. Bookmark this page for efficient monitoring of Oncolytics' progress in transforming cancer treatment through viral immunotherapy approaches.

Rhea-AI Summary

Oncolytics Biotech Inc. has received regulatory clearance to evaluate pelareorep in combination with modified FOLFIRINOX and an anti-PD-L1 inhibitor in pancreatic cancer. The company will start enrollment in a new GOBLET study cohort, supported by a $5M grant from PanCAN, with the first patient expected to be enrolled in Q2 2024. The study aims to enhance pelareorep's potential in addressing pancreatic cancer and expand its role in providing benefits to patients.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.08%
Tags
none
-
Rhea-AI Summary

Oncolytics Biotech® Inc. (NASDAQ: ONCY) will participate in a fireside chat at the 2024 RBC Capital Markets Global Healthcare Conference. Dr. Matt Coffey, the CEO, will be speaking at the event taking place on May 14-15, 2024, in New York. The company will also hold one-on-one investor meetings and provide a live webcast of the presentation on its website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.84%
Tags
conferences
-
Rhea-AI Summary

Oncolytics Biotech® announced a conference call and webcast to discuss corporate updates and financial results for the first quarter of 2024. The event will take place on May 9, 2024, at 4:30 p.m. ET.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.83%
Tags
conferences earnings
Rhea-AI Summary
Oncolytics Biotech® Inc. announces the acceptance of two abstracts at the 2024 American Society of Clinical Oncology Annual Meeting. The abstracts focus on pelareorep combined with modified FOLFIRINOX +/- atezolizumab in patients with metastatic pancreatic ductal adenocarcinoma and blood TIL expansion in patients with pancreatic, breast, and colon cancer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.89%
Tags
conferences
-
Rhea-AI Summary
Oncolytics Biotech Inc. announces a Type C meeting request with the FDA for a registration-enabling trial in HR+/HER2- metastatic breast cancer. Positive results from the BRACELET-1 trial and upcoming overall survival data in H2 2024 indicate a transformative year ahead.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.77%
Tags
none
-
Rhea-AI Summary
Oncolytics Biotech® Inc. President and CEO, Dr. Matt Coffey, will join the Viral Approaches in Oncology panel at Canaccord Genuity's Horizons in Oncology Virtual Conference on April 15, 2024. The company will also hold virtual investor meetings at the conference.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.94%
Tags
conferences
Rhea-AI Summary
Oncolytics Biotech Inc. announces positive 2023 data, advancements in pancreatic cancer studies, and expansion of pelareorep potential in various cancer cohorts. The company reported impressive results from the GOBLET study in anal carcinoma and plans to initiate a registration-enabling study in pancreatic cancer in 2024. The cash position of $34.9 million provides financial stability through critical milestones into 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.96%
Tags
-
Rhea-AI Summary
Investorideas.com issues a sector snapshot on pancreatic cancer treatments, highlighting Oncolytics Biotech® Inc. The global pancreatic cancer market is projected to grow at a CAGR of 18% between 2024 and 2036, reaching a revenue of USD 36 billion by 2036.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.97%
Tags
none
-
Rhea-AI Summary
Oncolytics Biotech Inc. announces a new Phase 1/2 cohort study evaluating pelareorep in combination with modified FOLFIRINOX with and without atezolizumab in pancreatic cancer patients. The study, supported by a US$5 million grant from PanCAN, aims to broaden the use of pelareorep in PDAC patients. The company is optimistic about the potential of this novel treatment approach to improve patient outcomes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.96%
Tags
none
Rhea-AI Summary
Oncolytics Biotech Inc. to host a conference call and webcast on March 7, 2024, to discuss corporate update and financial results for Q4 and full year 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-17.86%
Tags
conferences earnings
Oncolytics Biotech Inc

Nasdaq:ONCY

ONCY Rankings

ONCY Stock Data

48.58M
82.87M
4.35%
1.62%
3.44%
Biotechnology
Healthcare
Link
Canada
Calgary